Login to Your Account

THE BIOWORLD BIOME: Our Habitat for All Things Science

'Obesity increases the risk for many chronic diseases'
HONG KONG – A study by researchers at the Duke-National University of Singapore Graduate Medical School (Duke-NUS) has identified a new means by which brown adipose tissue is regulated in the body, which offers an attractive new target for the development of new anti-obesity treatments.
HONG KONG – The discovery of cancer-associated functions of a ligase enzyme and the gene encoding for it by researchers from Singapore, China and the U.S. may lead to the development of a new approach to the treatment of glioma.
AAN 2015
Efforts to develop remyelinating therapies in multiple sclerosis (MS) might have stolen some of the headlines heading into the American Academy of Neurology's (AAN) 67th Annual Meeting in Washington, but there are still plenty of data on traditional approaches to MS treatment on hand this week – some 500 presentations altogether – beginning with a slew of posters unveiled today.
AACR 2015
PHILADELPHIA – Patients treated with Merck & Co Inc.'s Keytruda (pembrolizumab) had better outcomes than could be achieved with their respective standards of care in melanoma and lung cancer trials. Results were presented Sunday at the annual meeting of the American Association for Cancer Research (AACR).
AACR 2015
Researchers and executives are gearing up for the annual meeting of the American Association for Cancer Research (AACR), which will be held in Philadelphia from April 18 - 22, where it's safe to say immuno-oncology will continue to rule the roost. Beyond the big data presentations of checkpoint inhibitors and CAR T cells themselves, among the most urgent question is how to help more patients realize the promise of immuno-oncology.
HONG KONG – Japanese scientists have used an advanced high-energy radiation particle accelerator to elucidate the structure of two receptors of the adipocyte-derived hormone, adiponectin, which could lead to the development of new treatments for obesity-related diseases, in particular type 2 diabetes.

Researchers for Alnylam Pharmaceuticals Inc. have published preclinical data for the company’s investigational hemophilia treatment ALN-AT3, which is currently undergoing phase I clinical testing and represents “a different approach to managing hemophilia,” senior author Akin Akinc told BioWorld Today. Hemophilia, the failure of blood to clot properly, can be due to lack of any one of a number of separate clotting factors. The most frequent forms of the disorder, hemophilia A and hemophilia B, are both X-linked and due to lack of Factor XIII and Factor IX, respectively.


Sovaldi (sofosbuvir, Gilead Sciences Inc.) is the poster child for recent breakthroughs in hepatitis C virus (HCV) treatment. Once curable only by grueling yearlong regimens with high dropout rates – and then only in half of all those who underwent the ordeal – Sovaldi is one cornerstone of more recent regimens that cure up to 90 percent of patients within 12 weeks. But at up to $84,000 for a course of treatment – roughly $1,000 per pill – Sovaldi is also the poster child for high drug prices, along with its sibling Harvoni (sofosbuvir/ledipasvir, Gilead Sciences Inc.).

A Sino-U.S. research collaboration has determined the atomic structure of the G protein-coupled P2Y1 receptor, which plays a key role in thrombus formation, challenging conventional concepts of drug action at GPC receptors and opening the door for future new drug discovery and development. The P2Y1 and P2Y12 purinergic receptors play a central physiological role in adenosine 5'-diphosphate-mediated platelet aggregation, which is an important component of thrombosis that can have potentially fatal consequences, including heart attack and stroke.

Cast Your Vote

Has biotech’s bubble burst?: